FDA grants Breakthrough Device designation to Natera multi-cancer blood test
NTRA•Natera received FDA Breakthrough Device designation for its multi-cancer early detection blood test, which uses cell-free DNA to screen for multiple cancers.
1. FDA designation
Natera received FDA Breakthrough Device designation for its multi-cancer early detection blood test. The assay uses cell-free DNA to screen for multiple cancers, supporting an accelerated regulatory review pathway.
